Walsh PC: Treatment of benign prostatic hyperplasia. N Engl J Med. 1996, 335: 557-563.
Google Scholar
Roos NP, Wennberg JE, Malenka DJ, Fisher ES, McPherson K, Andersen TF, Cohen MM, Ramsey E: Mortality and reoperation after open and transurethral resection of the prostate for benign prostatic hyperplasia. N Engl J Med. 1989, 320: 1120-1124.
Article
CAS
PubMed
Google Scholar
Bruskewitz RC, Larsen EH, Madsen P, Dorflinger T: 3-year follow-up of urinary symptoms after transurethral of the prostate. J Urol. 1986, 136: 613-615.
CAS
PubMed
Google Scholar
Roehrborn C, McConnell J, Barry M, Benaim E, Bruskewitz R, Blute M: AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: diagnosis and treatment recommendations. J Urol. 2003, 170: 530-547. 10.1097/01.ju.0000078083.38675.79.
Article
Google Scholar
Jankovic J, Brin MF: Therapeutic uses of botulinum toxin. N Engl J Med. 1991, 324: 1186-1194.
Article
CAS
PubMed
Google Scholar
MacKenzie I, Burnstock G, Dolly JO: The effects of purified botulinum neurotoxin type A on cholinergic, adrenergic and non-adrenergic, atropine-resistant autonomi neuromuscular transmission. Neuroscience. 1982, 7: 997-1006. 10.1016/0306-4522(82)90056-2.
Article
CAS
PubMed
Google Scholar
Smith CP, Chancellor MB: Emerging Role of botulinum toxin in the treatment of voiding dysfunction. J Urol. 2004, 171: 2128-2137. 10.1097/01.ju.0000127725.48479.89.
Article
CAS
PubMed
Google Scholar
Phelan MW, Franks M, Somogyi GT, Yokoyama T, Fraser MO, Lavelle JP, Yoshimura N, Chancellor MB: Botulinum toxin urethral sphincter injection to restore bladder emptying in men and women with voiding dysfunction. J Urol. 2001, 165: 1107-1110. 10.1097/00005392-200104000-00011.
Article
CAS
PubMed
Google Scholar
Kuo HC: Effect of botulinum a toxin in the treatment of voiding dysfunction due to detrusor underactivity. Urology. 2003, 61: 550-554. 10.1016/S0090-4295(02)02541-4.
Article
PubMed
Google Scholar
Smith CP, Franks MF, McNeil BK, Ghosh R, deGroat WC, Chancellor MB, Somogyi GT: Effect of botulinum toxin A on the autonomic nervous system of the rat lower urinary tract. J Urol. 2003, 169: 1896-1900. 10.1097/01.ju.0000049202.56189.54.
Article
CAS
PubMed
Google Scholar
Doggweiler R, Zermann DH, Ishigooka M, Schmidt RA: Botox induced prostatic involution. Prostate. 1998, 37: 44-50. 10.1002/(SICI)1097-0045(19980915)37:1<44::AID-PROS7>3.0.CO;2-8.
Article
CAS
PubMed
Google Scholar
Maria G, Brisinda G, Civello IM, Bentivoglio AR, Sganga G, Albanese A: Relief by botulinum toxin of voiding dysfunction due to benign prostatic hyperplasia: results of a randomized, placebo-controlled study. Urology. 2003, 62: 259-265. 10.1016/S0090-4295(03)00477-1.
Article
PubMed
Google Scholar
Chuang YC, Chiang PH, Huang CC, Yoshimura N, Chancellor MB: Botulinum toxin type A improves benign prostatic hyperplasia symptoms in patients with small prostates. Urology. 2005, 66: 775-779. 10.1016/j.urology.2005.04.029.
Article
PubMed
Google Scholar
Kuo HC: Prostate Botulinum toxin A injection- an alternative treatment for benign prostatic obstruction in poor surgical candidates. Urology. 2005, 65: 670-674. 10.1016/j.urology.2004.10.077.
Article
PubMed
Google Scholar
Lin ATL, Chen MT, Chiang H, Yang CH, Chang LS: Effect of orchiectomy on the alpha adrenergic contractile response of dog prostate. J Urol. 1995, 154: 1930-1933. 10.1016/S0022-5347(01)66828-9.
Article
CAS
PubMed
Google Scholar
Levy DA, Cromeens DM, Evans R, Stephens LC, von Eschenbach AC, Pisters LL: Transrectal ultrasound-guided intraprostatic injection of absolute ethanol with and without carmustine: a feasibility study in the canine model. Urology. 1999, 53: 1245-1251. 10.1016/S0090-4295(99)00043-6.
Article
CAS
PubMed
Google Scholar
Chiang P-H, Chuang Y-C, Huang C-C, Chiang C-P: Pilot study of transperineal injection of dehydrated ethanol in the treatment of prostatic obstruction. Urology. 2003, 61: 797-801. 10.1016/S0090-4295(02)02514-1.
Article
PubMed
Google Scholar
Gavrieli Y, Sherman Y, Ben-Sasson SA: Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol. 1992, 119: 493-501. 10.1083/jcb.119.3.493.
Article
CAS
PubMed
Google Scholar
Cockett A, Aso Y, Denis L: Prostate symptom score and quality of life assessment. Proceedings of the 2nd International Consultation on Benign Prostatic Hyperplasia (BPH) Paris. Edited by: Cockett ATK, Khoury S, Aso Y, et al. 1994, Jersey, Channel Island, Scientific Communication International, 553-555. June 27–30, 1993
Google Scholar
Lepor H, Baumann M, Shapiro E: Identification and characterization of alpha 1 adrenergic receptors in the canine prostate using [125I]-Heat. J Urol. 1987, 138: 1336-1339.
CAS
PubMed
Google Scholar
Lau WA, Pennefather JN, Mitchelson FJ: Cholinergic facilitation of neurotransmission to the smooth muscle of the guinea-pig prostate gland. British J Pharmacology. 2000, 130: 1013-1020. 10.1038/sj.bjp.0703409.
Article
CAS
Google Scholar
Niu YJ, Ma TX, Zhang J, Xu Y, Han RF, Sun G: Androgen and prostatic stroma. Asian J Androl. 2003, 5: 19-26.
CAS
PubMed
Google Scholar
Chuang YC, Huang CC, Kang HY, Chiang PH, de Miguel F, Yoshimura N, Chancellor MB: Novel action of Botulinum toxin on the stromal and epithelial components of prostate gland. J Urol. 2006, 173: 1158-1163. 10.1016/S0022-5347(05)00318-6.
Article
Google Scholar
Kyprianou N: Doxazosin and terazosin suppress prostate growth by inducing apoptosis: clinical significance. J Urol. 2003, 169: 1520-1525. 10.1097/01.ju.0000033280.29453.72.
Article
CAS
PubMed
Google Scholar